Biogen Inc.
BIIBHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBiogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. With a market capitalization of $37.27B, it sits in large-cap territory. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
Market Cap
$37.27B
Beta
0.09
P/E (TTM)
44.81
P/E (Fwd)
15.34
EPS (TTM)
$5.63
EPS (Fwd)
$16.44
ROE
4.6%
ROA
5.2%
Cash
$1.28B
Total Debt
$8.36B
Free CF
$1.27B
52W Change
67.7%
Annual Financials
Cash vs Debt
Where BIIB stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, BIIB finished 16.45% above its 150-day moving average ($202.11) and 19.13% above its 200-day moving average ($197.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIIB overbought or oversold?
At the October 16, 2026 close, BIIB's RSI(14) was 60.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BIIB has $1.28B in cash with $8.36B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $1.27B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 4.6%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $10.17B (2022) to $9.89B (2025).
With a beta below 0.7, Biogen Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing BIIB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.